Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06302439 · ClinicalTrials.gov registry record
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
A clinical trial of ATP-Binding Cassette Subfamily C Member 6 Deficiency and Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, sponsored by Inozyme Pharma.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 14
- Study locations
NCT06302439 is a study of ATP-Binding Cassette Subfamily C Member 6 Deficiency and Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency that is actively recruiting participants, run by Inozyme Pharma. The registered enrollment target is 1,000 participants. The trial reports 14 study locations across 7 states.
The verdict
NCT06302439, a study of ATP-Binding Cassette Subfamily C Member 6 Deficiency and Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, is actively recruiting participants, sponsored by Inozyme Pharma.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes \[PROs\]) of each disease during routine, standard-of-care visits, with the aim of developing a comprehensive understanding of the burden of illness and progressive nature of the disease.
Conditions Studied
Interventions
- OTHER No Intervention for this observational study
Study Locations (14)
Other
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
- IRCCS San Raffaele Hospital - Main - Milan
- The University of Tokyo Hospital - Tokyo
- Royal Hospital Muscat - Muscat
- EU Hub - VCTC - Barcelona
- Hospital Sant Joan de Deu - Barcelona
- Umraniye Training and Research Hospital - Istanbul
- VCTC - Derby
Illinois
- Ann and Robert H. Lurie Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
New Jersey
- CLINILABS Drug Development Corp - Eatontown
Pennsylvania
- The Children's Hospital of Philadelphia (CHOP) - Philadelphia
Quebec
- CHU Sainte-Justine Research Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2034-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06302439
The ClinicalTrials.gov registry entry for NCT06302439 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with ATP-Binding Cassette Subfamily C Member 6 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No Intervention for this observational study is the first listed.
NCT06302439 reports 14 study locations spanning 7 distinct geographic areas - top geographies include Other, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06302439 about?
NCT06302439 is a clinical study titled "PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency". The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudina...
What is the current status of trial NCT06302439?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-07-25. Estimated completion is 2034-05.
What conditions does trial NCT06302439 study?
This clinical trial studies the following conditions: ATP-Binding Cassette Subfamily C Member 6 Deficiency, Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency.
What interventions are being tested in trial NCT06302439?
The interventions under investigation include: No Intervention for this observational study (OTHER).
Who is sponsoring clinical trial NCT06302439?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06302439 being conducted?
This trial has 14 study locations across Illinois, Massachusetts, Minnesota, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ATP-Binding Cassette Subfamily C Member 6 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
ATP-Binding Cassette Subfamily C Member 6 Deficiency
All registered trials for this condition
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.